Absence of Δ-9-tetrahydrocannabinol dysphoric effects in dynorphin-deficient mice

Journal of Neuroscience

Volumn 21, Issue 23, 2001, Pages 9499-9505

  Zimmer, A ^a   Valjent, E ^a   Konig M ^a   Zimmer, A M ^a   Robledo, P ^a   Hahn, H ^a   Valverde, O ^a   Maldonado, R ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Addiction; Cannabinoid; Mice; Mutation; Opioid; Place aversion; Withdrawal

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE METHANESULFONATE; CANNABIS; DYNORPHIN; MORPHINE; OPIATE; TETRAHYDROCANNABINOL;

ANIMAL TISSUE; ARTICLE; CONDITIONING; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG WITHDRAWAL; DYSPHORIA; GENE EXPRESSION; GENE INACTIVATION; GENE LOCATION; GENETIC ANALYSIS; LOCOMOTION; MOUSE; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL;

EID: 0035576146     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.21-23-09499.2001     Document Type: Article

References (60)

1. Competitive and non-competitive NMDA antagonists limit dynorphin A-induced rat hindlimb paralysis
2. Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats
3. Control of pain initiation by endogenous cannabinoids
4. Cannabinoid receptors and reward in the rat: A conditioned place preference study
5. Delta 9-Tetrahydrocannabinol increases proopiomelanocortin gene expression in the arcuate nucleus of the rat hypothalamus
6. Delta-9-Tetrahydrocannabinol increases prodynorphin and proenkephalin gene expression in the spinal cord of the rat
7. Repeated administration of delta9-tetrahydrocannabinol produces a differential time related responsiveness on proenkephalin, proopiomelanocortin and corticotropin releasing factor gene expression in the hypothalamus and pituitary gland of the rat
8. Expression of mu opioid receptor mRNA in rat brain: An in situ hybridization study at the single cell level
9. 3H]CGP-39653 binding to rat brain membranes
10. Emotional response to intravenous delta-9-tetrahydrocannabinol during oral surgery
11. Cannabinoid receptor localization in brain: Relationship to motor and reward systems
12. Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study
13. Morphine-dependent rats: Blockade of precipitated abstinence by tetrahydrocannabinol
14. Dynorphin B and spinal analgesia: Induction of antinociception by the cannabinoids CP55,940, Delta(9)-THC and anandamide
15. Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with delta-9-tetrahydrocannabinol
16. Assessment of SNC 80 and naltrindole within a conditioned taste aversion design
17. Opioids: First lessons from knockout mice
18. Drugs of abuse: Anatomy, pharmacology and function of reward pathways
19. Neural substrates of opiate withdrawal
20. Effect of an acute dose of delta 9-THC on hypothalamic luteinizing hormone releasing hormone and metenkephalin content and serum levels of testosterone and corticosterone in rats
21. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice
22. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)tetrahydrocannabinoI and morphine-dependent mice
23. Reduction of morphine abstinence in mice with a mutation in the gene encoding CREB
24. Absence of opiate rewarding effects in mice lacking dopamine D2 receptors
25. Opioid-receptor mRNA expression in the rat CNS: Anatomical and functional implications
26. Immunohistochemical localization of the cloned mu opioid receptor in the rat CNS
27. Chronic administration of cannabinoids regulates proenkephalin mRNA levels in selected regions of the rat brain
28. Pharmacological and biochemical interactions between opioids and cannabinoids
29. Structural requirements for cannabinoid-induced antinociceptive activity in mice
30. Cocaine, but not morphine, induces conditioned place preference and sensitization to locomotor responses in CB1 knockout mice
31. Reduction of opioid dependence by the CB(1) antagonist SR141716A in mice: Evaluation of the interest in pharmacotherapy of opioid addiction
32. Cannabinoid modulation of dynorphin A: Correlation to cannabinoid-induced antinociception
33. Localization of cannabinoid receptor mRNA in rat brain
34. An analgesia circuit activated by cannabinoids
35. Functional interaction between opioid and cannabinoid receptors in drug self-administration
36. Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55,940 in the spinal cord
37. A role for central cannabinoid and opioid systems in peripheral delta 9-tetrahydrocannabinolinduced analgesia in mice
38. Corticotropin-releasing factor (CRF) antagonist [D-Phe12,Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats
39. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal
40. Endogenous cannabinoids as an aversive or counter-rewarding system in the rat
41. Motivational properties of opioids: Evidence that an activation of δ-receptors mediates reinforcement processes
42. Nonopioid motor effects of dynorphin A and related peptides: Structure dependence and role of the N-methyl-D-aspartate receptor
43. Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal
44. K2 opioid receptors in limbic areas of the human brain are upregulated by cocaine in fatal overdose victims
45. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mul opioid receptor mechanism
46. Psychiatric symptoms in cannabis users
47. A behavioural model to reveal place preference to delta 9-tetrahydrocannabinol in mice
48. Cannabinoid withdrawal syndrome is reduced in pre-proenkephalin knock-out mice
49. Delta9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: Reduction in morphine withdrawal syndrome without change in rewarding effect
50. Anandamide decreases naloxone-precipitated withdrawal signs in mice chronically treated with morphine
51. Pronociceptive actions of dynorphin maintain chronic neuropathic pain
52. Marijuana and medicine: Assessing the science base: A summary of the 1999 Institute of Medicine report
53. Effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamopituitary-adrenal axis in the rat
54. Blockade of cannabinoid-induced antinociception by norbinaltorphimine, but not N,N -diallyl-tyrosine-Aib-phenylalanineleucine, ICI 174,864 or naloxone in mice
55. Synergistic interactions of endogenous opioids and cannabinoid systems
56. Cannabinoids in clinical practice
57. Endogenous cannabinoid, 2-arachidonoylglycerol, attenuates naloxone-precipitated withdrawal signs in morphine-dependent mice
58. Dynorphin A as a potential endogenous ligand for four members of the opioid receptor gene family
59. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice